anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Malaria accounts for 500 million febrile illnesses and more than a million deaths annually. The disease burden is heaviest in economically developing countries where it is estimated that up to 5 percent of the gross domestic product of sub-Saharan countries is consumed by the direct and indirect health costs of malaria. Researchers propose to conduct a Phase I dosage-escalating study to assess the safety and immunogenicity of 3 different dosages of erythrocyte-binding antigen 175 kDA region II-nonglycosylated (EBA-175 RII-NG) recombinant Plasmodium falciparum (Pf) vaccine adjuvanted with Adju-Phos (aluminum phosphate adjuvant): 5, 20, and 80 micrograms (mcg), given in 3 doses at 0, 1, and 6 months by intramuscular (IM) injection to healthy young adults in a malaria endemic area (semi-immune adults). One dose of vaccine will be given at each time point. The primary objective is to assess the safety and reactogenicity (tolerability) of ascending dosages of EBA-175 RII-NG vaccine among healthy subjects given in 3 IM doses at 0, 1 and 6 months. The secondary objective is to evaluate the immunogenicity of the EBA-175 RII-NG vaccine by measuring anti-EBA-175 RII-NG antibodies using enzyme-linked immunosorbent assay (ELISA), inhibition of Plasmodium falciparum growth in vitro, and inhibition of binding of EBA-175 RII-NG to red blood cells (RBCs). Participants will include 60 malaria semi-immune healthy subjects between the ages of 18 and 40 years, males and females, recruited from Accra, Ghana. Subjects will be randomized to receive 3 doses of the vaccine or saline placebo by the intramuscular route in a 9:1 ratio at 0, 1 and 6 months. The safety and immunogenicity of ascending dosages of the vaccine will be assessed. Eighteen subjects will receive vaccine at each of the following dosage levels: 5, 20, and 80 mcg. Two subjects will receive placebo for each dosage level. Dosage escalation will proceed only after review of the 2-week safety data of the 2 initial doses of the prior dosage level.
Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and/or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.
Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
Elderly women are more susceptible to the development of chronic non-communicable diseases. Among these, diabetes mellitus (DM) and systemic arterial hypertension (SAH) stand out. This work aimed to carry out an expanded study on the interactions of anthropometric, biochemical and inflammatory parameters associated with the risk of severity in elderly women with hypertension and diabetes. The study involved the evaluation of 126 elderly women with hypertension and diabetes mellitus. The women were divided according disease severity (low, moderate, high and very high). Anthropometric data were collected by bioimpedance analysis. The inflammatory and biochemical data were obtained from volunteer blood samples. Waist circumference, waist circumference/height ratio, and systolic and diastolic pressures increased with severity. Biochemical marker levels increased with risk of severity, except HDLc. In the very high risk group, there was a higher IL-1β, IFN-γ and TNF-α production, however, lower IL-10 levels were observed. The very high risk group showed change values for the IL-10/IL-1β, IL-10/IL-17 and IL-10/TNF-α ratios. The results showed to be extensively altered in the very high risk group, where the inflammatory profile loses its responsiveness. This is the first study that shows an expanded view of the different parameters evaluated in elderly women with hypertension and diabetes.
Participants provided conventional therapy will perform various standardized exercise tasks during 40 minutes of 1 hr sessions. The type of therapeutic activities is based on published normative data of typical activities performed during clinical physical therapy sessions with focus on strengthening activities (25% of session); balance activities (25%); locomotor activities (25%), and combined stretching exercises (10-15%) and transfers (10-15%). Intensity of activities will be targeted at 30-40% of their HR reserve in attempts to maintain consistent intensities between training groups.
NEW MATERIAL:The aristlochin derivative of formulaI(R<1> is H or methyl; R<2> is methoxy; R<3> is group of formula II) and its salt. EXAMPLE:The compound of formula III. USE:Carcinostatic agent. PROCESS:For example, the stalk of KANBOKUTSU (Aristolochia manshuriensis, komarov.) of Chinese or Korean origin is crushed to tiny pieces and extracted with methyl alcohol at 0-35 deg.C for about 20 days. The extract is distilled under reduced pressure, and the residue is dissolved in n-butyl alcohol, and separated and purified by e.g. chromatography to obtain the compound of formula III, which is a compound of formulaIwherein R<1> is H. The compound of formula III can be converted to another form of the compound of formulaIwherein R<1> is methyl by reacting with e.g. diazomethane in a solvent e.g. benzene preferably at 0-5 deg.C thereby effecting methyl esterification.
This group will receive an educational program based . This group, as the other group, during phase 1 and phase 3, will review the medical records of the last 40 patients (for each phase) with known T2DM and hospitalized for any cause.
Systems and methods for awareness machines and artificial intelligence (AI) based community wide care that may monitor one or more event in one or more domain are described. In an embodiment, a community wide care may monitor one or more event in real-time. In another embodiment, a multifaceted community wide care may enhance intelligence and awareness regarding one or more event. A functional performance measure (FPM) is described for the community wide care and the multifaceted community wide care. In an embodiment, one or more FPM for a community wide care may be evaluated to analyze performance and viability of the community wide care. The one or more FPM may be formulated with one or more metric, which may be computed to derive one or more performance indicator for the community wide care.
PROBLEM TO BE SOLVED: To provide a genistein-containing preparation capable of maintaining a therapeutic plasma level of genistein, which is a pharmacologically active isoflavone over a long period of time.SOLUTION: According to the present invention, there is provide genistein containing formulation that comprises nanoparticulate genistein (structure shown below), and a nonionic surfactant and an excipient selected from a water-soluble polymer, diluent, buffer so as to form a suspension medium of the nanoparticulate genistein. Here, the nanoparticulate genistein exhibits a D (0.50) of 0.5 μm or less. The nanoparticulate genistein is at a concentration of 250 mg/mL or more. The nonionic surfactant is preferably polysorbate 80 or polysorbate 20. The water-soluble polymer is preferably polyvinylpyrrolidone. The buffer solution is preferably a sodium phosphate buffer solution. The diluent is preferably a sodium chloride solution.SELECTED DRAWING: None
Pentetreotide is a DTPA conjugate of octreotide, which is a long-acting analog of the human hormone, somatostatin. Indium In 111 pentetreotide binds to somatostatin receptors on cell surfaces throughout the body. Within an hour of injection, most of the dose of indium In 111 pentetreotide distributes from plasma to extravascular body tissues and concentrates in tumors containing a high density of somatostatin receptors. After background clearance, visualization of somatostatin receptor-rich tissue is achieved. In addition to somatostatin receptor-rich tumors, the normal pituitary gland, thyroid gland, liver, spleen and urinary bladder also are visualized in most patients, as is the bowel, to a lesser extent. Excretion is almost exclusively via the kidneys.
PURPOSE:To provide a polymer gel for medical treatment having a medicine releasing characteristic according to the quantity of enzyme by immobilizing a medicine to a water swellable polymer gel via a decomposable group of which main chain is cut by anzyme reaction and a spacer by the conjugation form expressed by a specific general formula. CONSTITUTION:This polymer gel for medical treatment is formed in the following manner. The medicine is immobilized in the water swellable polymer gel via the decomposable group of which main chain is cut by enzyme reaction and the spacer by the conjugation form expressed by a general formula A-B-C-D (where, A denotes the water swellable polymer gel, B denotes the spacer, C denotes the decomposable group obtd. by cutting its main chain the enzyme reaction and D denotes medicine, respectively). As a result, the medicine releasing characteristic meeting the quantity of the enzyme is assured, thereby, the medicine of the amt. effective for treatment is released only at the lesion where enzyme is produced. Then, the polymer gel for medical medical treatment described above is capable of promoting wound healing when applied to a wound coating material, etc.
Malignant arrhythmias are associated with high mortality and morbidity after coronary artery bypass graft (CABG) operations. Heart rate variability (HRV) is a physiological indicator of the effects of activity on heart ANS rate and has prognostic value for cardiac mortality. Spectral analysis of HRV can provide an assessment of adrenergic and cholinergic system activities during anesthesia. With the "power spectral" analysis of HRV, important clinical information can be obtained about the effects of anesthesia on the autonomic nervous system and the central nervous system. Decrease in HRV has a prognostic value for cardiac-induced mortality. The disease, which is transferred to intensive care unit (ICU) after CABG, is sedated with different medicines until the time of extubation. One commonly used sedative drug is deksmedetomidine, an α2 receptor agonist. Alpha 2 (α2) receptor agonist drugs reduce myocardial oxygen consumption and heart rate with sympatholytic properties. Therefore, deksmedetomidine can be safely and effectively used in patients undergoing cardiac surgery without pro-tachyarrhythmic and / or negative inotropic effects.In this study, it was aimed to investigate electrophysiologic effects of cardiac autonomic system by using HRV analysis in dexmedetomine and midazolam patients who underwent elective CABG and were used for sedation in the postoperative period.
PURPOSE: To identify independent predictors of urinary continence and report early complications after radical prostatectomy (RP) in a large, contemporary German cohort.
METHODS: Urinary incontinence data of patients undergoing 3-week inpatient rehabilitation (IR) after RP were prospectively assessed by 24-hr pad test and uroflowmetry at the beginning and the end of IR, respectively. Lymphoceles were assessed prospectively by ultrasound. Tumor and patient characteristics, and information on urinary leakage on initial cystography were retrospectively extracted from discharge letters and surgical reports. Regression analyses were performed to identify predictors of urinary continence at the beginning of IR.
RESULTS: Overall, 2,141 patients were included in the final analyses. Anastomotic leakage on the initial cystography and lymphoceles were found in 11.4% and 30.8% of patients, respectively. Intervention for a symptomatic lymphocele was required in 4.2% of patients. At the end of IR, 54.2% of patients were continent, while the median urine loss decreased to 73 g (interquartile range 15-321). Multivariable logistic regression analysis identified age and diabetes mellitus as independent negative predictors, but nerve-sparing surgery as an independent positive predictor of urinary continence (each p < 0.001). Multivariable linear regression analysis showed that 24-hr urine loss increased by 7 g with each year of life (p < 0.001), was 79 g higher in patients with diabetes mellitus (p = 0.007), and 175 g lower in patients with NS (p < 0.001).
CONCLUSION: Age, diabetes mellitus, and NS are significantly associated with continence outcomes in the early period after RP. Our analyses may help clinicians to pre-operatively counsel patients on potential surgical outcomes.
Our previous work has demonstrated protein kinase D2 (PKD2) played a critical influence in experimental colitis in animal. However, the role of PKD2 in human norovirus (HuNoVs)-induced diarrhea remained unknown. Aquaporin 3 (AQP3) expression, a critical protein mediating diarrhea, was assessed by western blot, qRT-PCR in intestinal epithelial cells (IECs). Luciferase, IF, IP and ChIP assay were used to explore the mechanism through which HuNoVs regulated AQP3. Herein, we found that AQP3 expression was drastically decreased in IECs in response to VP1 transfection, the major capsid protein of HuNoVs, or HuNoVs infection. Mechanistically, HuNoVs triggered phosphorylation of PKD2 through TLR2/MyD88/IRAK4, which further inhibited AP2γ activation and nuclear translocation, leading to suppress AQP3 transactivation in IECs. Most importantly, PKD2 interacted with MyD88/IRAK4, and VP1 overexpression enhanced this complex form, which, in turn, to increase PKD2 phosphorylation. In addition, endogenous PKD2 interacted with AP2γ, and this interaction was enhanced in response to HuNoVs treatment, and subsequently resulting in AP2γ phosphorylation inhibition. Moreover, inhibition of PKD2 activation could reverse the inhibitory effect of HuNoVs on AQP3 expression. In summary, we established a novel mechanism that HuNoV inhibited AQP3 expression through TLR2/MyD88/IRAK4/PKD2 signaling pathway, targeting PKD2 activity could be a promising strategy for prevention of HuNoVs-induced gastroenteritis.
Gastroesophageal reflux disease (GERD) is a widely prevalent medical disorder in the United States with a spectrum of treatment options ranging from dietary modification, to various pharmacologic treatments, to an array of available surgical and endoscopic procedures. There is a well-described correlation between obesity and symptoms of GERD. The morbidly obese patients undergoing evaluation for bariatric surgery are to characterize any GERD-like symptoms as this will assist in directing surgical therapy. Generally, it is recommended that patients with severe GERD undergo Roux-en-Y gastric bypass(RYGB) rather than a sleeve gastrectomy (SG) as RYGB has proven to be the most effective surgical treatment for GERD in the morbidly obese patient. The number of bariatric procedures performed in the United States has increased significantly in the recent years. Out of all bariatric procedures SG is the most commonly performed in the United States, as it has proven to be a very safe procedure with excellent weight loss. However, the incidence of de novo GERD and the effect of SG on patients with preexisting GERD remain controversial. Although some authors report high incidence of de novo GERD and worsening of previous reflux symptoms, there is also data showing improvement of symptoms post SG. Management of GERD after SG poses an interesting challenge, as traditional invasive procedures like Nissen fundoplication are not available due to an altered gastric anatomy. The alternative is to perform a conversion to RYGB, which represents increased morbidity to patient and significant cost.

A large number of endoscopic procedures have been introduced in the past for the management of GERD as an alternative to the surgical anti-reflux procedures with various degrees of success. One of the few non-invasive methods for managing GERD that is still available on the market and widely used is Stretta. Stretta delivers Radio Frequency energy (RFe) to the LES resulting in increased LES pressure. In 2000, the FDA approved the Stretta system for treatment of GERD. Stretta allows an alternative for treatment in patients who are not willing or able to undergo surgery. The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) published clinical practice guidelines that endorsed Stretta as an appropriate therapy for treatment of GERD in patients \>18, with at least 6 months of symptoms partially or completely responsive to pharmacotherapy and who are unable or unwilling to undergo laparoscopic Nissen fundoplication. There are to date no studies evaluating the use of Stretta in management of patients with GERD symptoms after sleeve gastrectomy.

The investigators will study sleeve gastrectomy patients with GERD symptoms and if considered candidates for Stretta all patients will be enrolled in data collection cohort and followed prospectively with symptom questionnaire and quality of life scores for improvement of symptoms.
FIELD: medicine. SUBSTANCE: polypeptide isolated from leech of species Hirudinaria manillensis has the following amino acid sequence: X-Y-Tyr-Thr-Asn-Cys-Thr-Gln-Ser-Gly-Gln-Asn-Tyr-Cys-Leu-Cys- Val-Gly-Ser-Asn-Val-Cys-Gly-Glu-Gly-Asp-Asn-Cys-Asn-D-Gln-Leu- Ser-Ser-Ser-Gly-Asn-Gln-Cys-Val-E-Gly-Gln---Gly-Thr-Pro-F-Pro- Gln-Gln-Ile-Pro-Asp-Gln-Z-Ile--Lys. In this sequence X, Y and Z are any amino acid residue; D Cys or Pro; E Gly or Asp or His; F Asp, Lys or Try, and also pharmaceutically acceptable salt, derivative or biological precursor on this base. Polypeptide and its fragments are specific antithrombins. EFFECT: leech polypeptide preparing. 5 cl, 6 dwg
A system for providing real-time bi-directional charge capture-centralized conversation between Billing and Provider entities, comprising a first computer apparatus with a computer apparatus charge capture module installed and a second computer apparatus with a computer apparatus billing module installed that are used to transmit and/or receive real-time charge capture centralized conversation data. Real-time charge capture-centralized conversation data is comprised of real-time charge capture data. The real-time charge capture data and the real-time charge capture-centralized conversation data can be combined to create real-time claim data. The system further comprises first computer apparatus and second computer apparatus receipt and transmission via secured communication links. The real-time charge capture data, real-time charge capture-centralized conversation data and real-time claim data is presented in a social media conversation style format. The first computer apparatus and second computer apparatus make it possible for both a Billing and a Provider entity to initiate, transmit or modify any of the sets of real-time charge capture data or real-time charge capture-centralized conversation data.
Head and Neck Cancer Patients 

In the placebo-controlled clinical trials (see Clinical Studies section) the mean age of patients was approximately 58 years (range 19 to 80). Of these patients, 97/369 (61/217 receiving pilocarpine) were over the age of 65 years. In the healthy volunteer studies, 15/150 subjects were over the age of 65 years. In both study populations, the adverse events reported by those over 65 years and those 65 years and younger were comparable. Of the 15 elderly volunteers (5 women, 10 men), the   
5 women had higher Cmax and AUC’s than the men. (See Pharmacokinetics section.) 

Sjogren’s Syndrome Patients 

In the placebo-controlled clinical trials (see Clinical Studies section), the mean age of patients was approximately 55 years (range 21 to 85). The adverse events reported by those over 65 years and those 65 years and younger were comparable except for notable trends for urinary frequency, diarrhea, and dizziness (see ADVERSE REACTIONS section).
NEW MATERIAL:M5071-Like substance M5094 substance having about 33,000 molecular weight and the following physical and chemical properties. Isoelectric point: approximately pH 3.5. Ultraviolet absorption spectrum: lambdamax 280mmu and lambdamax (sh) 290mmu. Solubility: readily soluble in water and insoluble in methanol, acetone, chloroform and ethyl acetate. Coloring reaction: positive in biuret reaction, xanthorproteic reaction and Folin reaction. Color property: white. Action: inhibiting synthesis of insoluble glucan by glucosyltransferase. pH stability: stable at pH 4-7. Thermostability: stable to 40 deg.C and being deactivated approximately 100% at 60 deg.C. USE:Preventing formation of insoluble glucan and tooth decay. PREPARATION:Nodulisporium sp. M5094 strain (FERM P-5800) is cultivated in a medium containing a carbon source and a nitrogen source and the aimed substance is isolated from a culture filtrate of the prepared culture mixture.
The invention provides a method for preparation of a fat-reducing preparation from pure traditional Chinese medicines. With the advantages of low price, easy popularization and good curative effect, etc., the fat-reducing preparation is composed of dry lotus leaves, hawthorn, thunberg fritillary bulb, raw rhubarb and tangerine peel in a formula proportion of (100-150):(200-250):(50-100):(20-50). The traditional Chinese medicines are ground into fine powder as the dosage of one treatment course. 50-100g of dry drugs are taken every day and are soaked by boiling water. 300ml of the liquor is taken, and is orally taken in two times, one month as a course of treatment. The dried lotus leaves mainly include the following chemical components: nuciferine, citric acid, malic acid, gluconic acid, oxalic acid and succinic acid, and other alkaline components with an anti-mitotic effect, and has the efficacy of antipyresis, bacteriostasis and spasmolysis. And the thunberg fritillary bulb has the efficacy of clearing heat and eliminating phlegm, depressing qi and relieving cough, removing stasis and eliminating swelling.
Participants in this group will be monitored to see if patients discontinuing maintenance of anti-HER-2 treatments with ctDNA monitoring in addition to radiologic imaging and routine blood work will stay in complete radiological remission. Participants will be in this group for up to 3 years.
PURPOSE: Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them are provided. CONSTITUTION: The present invention relates to Tumor Necrosis Factor Related ligand or "TRELL", a polypeptide which is a member of the Tumor Necrosis Factor Family. The protein or its receptor may have anti-cancer and/or immunoregulatory applications. Furthermore, cells transfected with the gene for TRELL may be used in gene therapy to treat tumors, autoimmune and inflammatory diseases or inherited genetic disorders. A DNA sequence encoding TRELL, said sequence consisting essentially of SEQ. ID. NO. 1 or SEQ. ID. NO. 3.